Thoracic Malignancies

Genomic Testing

Questions discussed in this category

Which patients with Stage II-III lung adenocarcinoma, in whom you are considering neoadjuvant chemoimmunotherapy, can you rely on liquid NGS to exclude driver mutations in lieu of repeat tissue biopsy?

Per NCCN exclusion of EGFR/ALK alterations at a minimum is recommended prior to consideration of neoadjuvant chemoimmunotherapy.

1 Answer available

Is there any role for re-biopsy and NGS for patients with NSCLC and KRAS G12C at time of progression after first line therapy before starting sotorasib, or after progression on sotorasib?

1 Answer available

Papers discussed in this category

N Engl J Med, 2021 Jun 24

Acquired Resistance to KRAS^G12C Inhibition in Cancer.

Related Topics in Thoracic Malignancies